Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 11, 2005, Pages 1457-1462

  Rosenthal, Ian M ^a   Williams, Kathy ^a   Tyagi, Sandeep ^a   Vernon, Andrew A ^a   Peloquin, Charles A ^a   Bishai, William R ^a   Grosset, Jacques H ^a   Nuermberger, Eric L ^a  

^a NONE

Author keywords

Antibiotics; Intermittent therapy; Mouse; Treatment

Indexed keywords

ISONIAZID; MOXIFLOXACIN; RIFAMPICIN; RIFAPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; AZA COMPOUNDS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 30344462670     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200507-1072OC     Document Type: Article

References (26)

1. Frieden T, Sterling T, Munsiff S, Watt C, Dye C. Tuberculosis. Lancet 2003;362:887-899.
2. World Health Organization. Global tuberculosis: control, surveillance, planning, financing. WHO/HTM/TB/2005.349. Geneva, Switzerland: World Health Organization; 2005.
3. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999;353:1843-1847.
4. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
5. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002;360:528-534.
6. Anonymous. Rifapentine (Priftin) data on file [package insert]. Kansas City, MO: Hoechst Marion Roussel; 1998.
7. Tam CM, Chan SL, Kam KM, Goodall RL, Mitchison DA. Rifapentine and isoniazid in the continuation phase of a 6-month regimen: final report at 5 years-prognostic value of various measures. Int J Tuberc Lung Dis 2002;6:3-10.
8. Mitchison DA. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 1998;2:612-615.
9. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327-341.
10. Weiner M, Bock N, Peloquin C, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, et al. Pharmacokinetics of rifapentine at 600, 900, and 1200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004;169:1191-1197.
11. Bock N, Sterling T, Hamilton C, Pachucki C, Wang Y, Conwell D, Mosher A, Samuels M, Vernon A. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med 2002;165:1526-1530.
12. Daniel N, Lounis N, Ji B, O'Brien R, Vernon A, Geiter L, Szpytma M, Truffot-Pernot C, Hejblum G, Grosset J. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Am J Respir Crit Care Med 2000;161:1572-1577.
13. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, Roscigno G, Norman J, McIlleron H, Mitchison DA.The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172:128-135.
14. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001;45:3482-3486.
15. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien, Vernon A, Chaisson RE, Bishai WR, Grosset J. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2003;169:421-426.
16. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien R, Vernon A, Chaisson R, Bishai W, Grosset J. Moxifloxacincontaining regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170:1131-1134.
17. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. Ann Intern Med 1990;112:407-415.
18. Rosenthal I, Nuermberger E, Tyagi S, Williams K, Lounis N, Peloquin C, Bishai W, Grosset J. Pharmacokinetics and pharmacodynamics of once-weekly moxifloxacin and rifapentine-based regimens for treatment of murine tuberculosis [abstract]. Proc Am Thorac Soc 2005;2:A272.
19. Wise R, Andrews J, Marshall G, Hartman G. Pharmacokinetics and inflammatory fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999;43:1508-1510.
20. Chang K, Leung C, Yew W, Ho S, Tam C. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004;170:1124-1130.
21. Vernon A, Iademarco M. In the treatment of tuberculosis, you get what you pay for.... Am J Respir Crit Care Med 2004;170:1040-1041.
22. Li J, Munsiff S, Driver C, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997. Clin Infect Dis 2005;41:83-91.
23. Grosset J, Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA, editors. Mycobacteria, Vol. II: Chemotherapy. New York: Chapman & Hall; 1998. pp. 51-97.
24. Sullivan J, Woodruff M, Lettieri J, Agarwal V, Krol G, Leese P, Watson S, Heller A. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999;43:2793-2797.
25. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992;36:548-551.
26. Ji B, Truffot-Pernot C, Lacroix M, Raviglione M, O'Brien R, Olliaro P, Roscigno G, Grosset J. Effectiveness of rifampin, rifabutin and rifapentine for preventative therapy of tuberculosis in mice. Am Rev Respir Dis 1993;148:1541-1546.